RT Journal Article
T1 Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study
T2 Reboxetina para el TDAH en niños que no responden o con mala tolerancia al metilfenidato: un estudio prospectivo abierto a largo plazo
A1 Quintero Gutiérrez Del Álamo, Francisco Javier
A1 López Muñoz, Francisco
A1 Alamo, Cecilio
A1 Loro, Mercedes
A1 García Campos, Natalia
AB Up to 30% of patients with attention-deficit hyperactivity disorder (ADHD) treated with psychostimulants discontinue the treatment because of intolerance or lack of therapeutic response. Therapeutic alternatives are needed for such patients. In the present case series, we study the effectiveness of reboxetine over a period of 6 months in a sample of 14 children diagnosed with ADHD according to DSM-IV-TR criteria, who had responded only partially or had presented poor tolerance to conventional treatment with methylphenidate. Clinical efficacy was evaluated through the application of the 18-item Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Percentages of responders (ADHD-RS ≥ 25%) and improvers (CGI-I absolute value < 4) were 90.9 and 72.7%, respectively. No serious side-effects were observed during treatment, the most frequent effects being headaches and insomnia. The initial findings of our study show that reboxetine may constitute an effective tool for long-term treatment of children with ADHD who present poor response or poor tolerance to initial treatment with methylphenidate.
PB Springer
SN 1866-6116
YR 2009
FD 2009
LK https://hdl.handle.net/20.500.14352/96576
UL https://hdl.handle.net/20.500.14352/96576
LA eng
NO uintero J, López-Muñoz F, Alamo C, Loro M, García-Campos N. Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study. Atten Defic Hyperact Disord. 2010 Nov;2(3):107-13. doi: 10.1007/s12402-010-0027-x. Epub 2010 May 25. PMID: 21432596
DS Docta Complutense
RD 6 abr 2025